HSP90 Inhibitors Central
A site dedicated to the cancer drug class targeting Heat Shock Protein 90 (HSP90). Featuring drug discovery, clinical development, business transaction, conference presentations, etc related to these drugs including ganetespib, AT13387, retaspimycin, 17-AAG and more.
HSP90 Inhibitors Central's Latest Posts
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ.The rapidly growing recognition of the role of oncogenic ROS1 fusion proteins in the malignant transformation of multiple cancers, including lung adeno [...]
See below for a couple of key data slides from the recent Synta Pharma $SNTA update on the ganetespib GALAXY-1 trial in NSCLC. If you missed them, see my recent posts with notes from the data webcast and [...]
Conference call excerpts from the Ariad Pharma $ARIA 3q-2013 earnings call c/o SeekingAlpha. For 113, we will focus only on ALK-positive lung cancer, both tr [...]
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancerWagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD.INTRODUCTION:The multitargeted tyrosine kinase inhibitor (TKI) crizotinib is act [...]
Log in to leave a comment